市場調查報告書

伴隨診斷市場-診斷的未來(2021-2025):來源,應用程序,預測/分析,COVID更新,執行和顧問指南

Companion Diagnostic Markets - The Future of Diagnostics. By Funding Source and Application with Customized Forecasting/Analysis, Covid Updates, and Executive and Consultant Guides 2021-2025

出版商 Howe Sound Research 商品編碼 969592
出版日期 內容資訊 英文 426 Pages
商品交期: 最快1-2個工作天內
價格
伴隨診斷市場-診斷的未來(2021-2025):來源,應用程序,預測/分析,COVID更新,執行和顧問指南 Companion Diagnostic Markets - The Future of Diagnostics. By Funding Source and Application with Customized Forecasting/Analysis, Covid Updates, and Executive and Consultant Guides 2021-2025
出版日期: 2020年11月06日內容資訊: 英文 426 Pages
簡介

本報告調查和分析了全球伴隨診斷市場,並提供了系統信息,例如市場定義和概述,市場趨勢,發展趨勢,主要國家/地區的詳細細分以及主要公司的概況。

目錄

i。伴侶診斷市場:戰略形勢分析

ii。高管,營銷,銷售和業務開發人員指南

iii。管理顧問和投資顧問指南

第1章簡介和市場定義

  • 什麼是伴隨診斷?
  • 定制醫療革命
  • 市場定義
    • 利潤市場規模
  • 調查方法
  • 臨床測試展望
    • 在美國用於臨床測試的Medicare支出

第2章市場概述

  • 動態市場參與者
    • 學術研究所
    • 診斷測試開發公司
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立測試機構
    • 國家/公共/區域研究所
    • 醫院實驗室
    • 診所
    • 審計機構
    • 認證機構
  • 定制醫療和陪伴診斷
    • 基本
    • 方法
    • 疾病風險評估
    • 應用
    • 診斷與乾預
    • 藥物開發和使用
    • 呼吸蛋白質組學
    • 癌症基因組學
    • 大眾檢查
    • 挑戰
    • 監管監控
    • 知識產權
    • 醫療費用報銷政策
    • 患者隱私和機密性
  • 染色體,基因和表觀遺傳學
    • 染色體
    • 基因
    • 表觀遺傳學
  • 癌症基因
    • 生殖細胞譜係與體細胞
    • 臨床角色的變化
  • 產業結構發揮作用
    • 新藥融資市場
    • 規模經濟
    • 臨床醫生
    • 醫生和POCT

第3章市場趨勢

  • 生長促進劑
    • 護理水平
    • 免疫腫瘤學
    • 責任
    • 老年人口
  • 生長抑製劑
    • 知識水平
    • 基因風暴
    • 協議抗性
    • 法規和範圍
  • 儀表和自動化
    • 設備是市場份額的關鍵
    • 生物信息學發揮作用
  • 診斷技術的發展
    • 下一代測序助推革命
    • 單一sergenomics改變了情況
    • 藥物基因組學掩蓋了診斷和治療
    • CGES測試,美好的新世界
    • 生物芯片/基於巨磁阻的分析

第4章伴隨診斷的最新發展

  • 最新動態:本節的重要性和用法
    • 這些發展的重要性
    • 如何使用本節

第5章主要公司簡介

  • 10x Genomics, Inc.
  • Abbott Diagnostic
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostic
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostic
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostic
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostic
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostic
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostic
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostic
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostic
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第6章全球伴侶診斷市場

  • 世界市場概況:按國家
  • 全球市場概述:按應用
  • 全球市場概述:按來源

第7章全球伴侶診斷市場:按應用

  • 腫瘤科
  • 神經病學
  • 心臟病學
  • 其他應用
目錄

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

" Companion Diagnostic Markets, the future of diagnostics. By Funding Source and Application with customized forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2021-2025" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail. Forecast demand for new testing regimes or technologies. Make research investment decisions. Specific growth and market size estimates for your area of interest is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Companion Diagnostic Market - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What are Companion Diagnostics?
  • 1.2 The Personalized Medicine Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Clinical Laboratory Testing
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Instrumentation Supplier
    • 2.1.4 Distributor and Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Office Labs
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Personalized Medicine and Companion Diagnostics
    • 2.2.1 Basics
    • 2.2.2 Method
    • 2.2.3 Disease risk assessment
    • 2.2.4 Applications
    • 2.2.5 Diagnosis and intervention
    • 2.2.5.1 Companion Diagnostics
    • 2.2.6 Drug development and usage
    • 2.2.7 Respiratory proteomics
    • 2.2.8 Cancer genomics
    • 2.2.9 Population screening
    • 2.2.10 Challenges
    • 2.2.11 Regulatory oversight
    • 2.2.12 Intellectual property rights
    • 2.2.13 Reimbursement policies
    • 2.2.14 Patient privacy and confidentiality
  • 2.3 Chromosomes, Genes and Epigenetics
    • 2.3.1 Chromosomes
    • 2.3.2 Genes
    • 2.3.3 Epigenetics
  • 2.4 Cancer Genes
    • 2.4.1 Germline vs Somatic
    • 2.4.2 Changing Clinical Role
  • 2.5 Structure of Industry Plays a Part
    • 2.5.1 New Pharmaceutical Funding Market
    • 2.5.2 Economies of Scale
    • 2.5.2.1 Hospital vs. Central Lab
    • 2.5.3 Physician Office Labs
    • 2.5.4 Physicians and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Level of Care
    • 3.1.2 Immuno-oncology
    • 3.1.3 Liability
    • 3.1.4 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 State of knowledge
    • 3.2.2 Genetic Blizzard
    • 3.2.3 Protocol Resistance
    • 3.2.4 Regulation and coverage
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Single Cell Genomics Changes the Picture
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies
  • Promega to Develop MSI Assay as CDx
  • HTG Molecular Q2 Revenues Drop 66 Percent
  • Guardant Health to Develop CDx for Janssen
  • Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • FDA Approval for FoundationOne®CDx
  • FDA finalizes CDx Guidance
  • QIAGEN Launches CDx Therascreen BRAF Test
  • Myriad Genetics Seeks Approval for Companion Diagnostic
  • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
  • QIAGEN Builds on Global Collaboration with Amgen
  • Foundation Medicine nabs 19th companion Dx
  • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostic
  • Myriad Wins Japanese Approval for BRACAnalysis
  • Fujitsu Improves Efficiency in Cancer Genomic Medicine
  • Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
  • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
  • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
  • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
  • Universal Genetic Testing for All Breast Cancer Patients
  • Exact Sciences buys Genomic Health
  • Biodesix Highlights Pipeline and Companion Diagnostic Development
  • Multi-Gene Liquid Biopsy Breast Cancer Panel
  • New Gene Panel Identifies High Risk Prostate Cancer
  • Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • Inivata Completes £39.8M Series B Funding Round
  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
  • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

  • 10x Genomics, Inc.
  • Abbott Diagnostic
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostic
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostic
  • Castle Biosciences, Inc.
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostic
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine (now Roche)
  • Freenome
  • FUJIFILM Wako Diagnostic
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostic
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostic
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostic
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostic
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostic
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostic
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for Companion Diagnostic

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Application - Overview
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Application - Base Year
    • 6.2.4 Chart - Global Market by Application - Final Year
    • 6.2.5 Chart - Global Market by Application - Share by Year
  • 6.3 Global Market Funding Source - Overview
    • 6.3.1 Table - Global Market by Funding Source
    • 6.3.2 Chart - Global Market Funding Source - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market Funding Source - Base Year
    • 6.3.4 Chart - Global Market Funding Source - Final Year
    • 6.3.5 Chart - Global Market Funding Source - Share by Year

7. Global Companion Diagnostic Markets - By Application

  • 7.1 Oncology
    • 7.1.1 Table Oncology - by Country
    • 7.1.2 Chart - Oncology Growth
  • 7.2 Neurology
    • 7.2.1 Table Neurology - by Country
    • 7.2.2 Chart - Neurology Growth
  • 7.3 Cardiology
    • 7.3.1 Table Cardiology - by Country
    • 7.3.2 Chart - Cardiology Growth
  • 7.4 Other Application
    • 7.4.1 Table Other Application - by Country
    • 7.4.2 Chart - Other Application Growth

8. Global Companion Diagnostic Markets - Funding Source

  • 8.1 Global Market Pharmaceutical
    • 8.1.1 Table Pharmaceutical - by Country
    • 8.1.2 Chart - Pharmaceutical Growth
  • 8.2 Global Market Venture
    • 8.2.1 Table Venture - by Country
    • 8.2.2 Chart - Venture Growth
  • 8.3 Global Market Clinical
    • 8.3.1 Table Clinical - by Country
    • 8.3.2 Chart - Clinical Growth
  • 8.4 Global Market Other Funding
    • 8.4.1 Table Other Funding - by Country
    • 8.4.2 Chart - Other Funding Growth

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. Pharmacogenomic Biomarkers in Drug Labeling

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Market Players by Type
  • Table 3 The Base Pairs
  • Table 4 Five Factors Driving Growth
  • Table 5 Four Factors Limiting Growth
  • Table 6 Key Diagnostic Laboratory Technology Trends
  • Table 7 Next Generation Sequencing Technologies - Speed and Cost
  • Table 8 Global Companion Diagnostic Market by Region
  • Table 9 Global Market by Application
  • Table 10 Global Market by Funding Source
  • Table 11 Oncology by Country
  • Table 12 Neurology by Country
  • Table 13 Cardiology by Country
  • Table 14 Other Application by Country
  • Table 15 Pharmaceutical by Country
  • Table 16 Venture by Country
  • Table 17 Clinical by Country
  • Table 18 Other Funding by Country
  • Table 19 Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1 FDA Approved Companion Diagnostics
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 DNA Strands and Chromosomes
  • Figure 4 Karyogram of Human Chromosomes
  • Figure 5 Size of Various Genomes
  • Figure 6 Germline vs Somatic Mutations
  • Figure 7 Comparing Genomic Diagnostic and Traditional Testing
  • Figure 8 Percentage of World Population Over 65
  • Figure 9 Base Year Country Market Share Chart
  • Figure 10 CDx Market by Application - Base vs. Final Year
  • Figure 11 CDx Market by Application Base Year
  • Figure 12 CDx Market by Application Final Year
  • Figure 13 Application Type Share by Year
  • Figure 14 Funding Source - Base vs. Final Year
  • Figure 15 Funding Source Market Base Year
  • Figure 16 Funding Source Market Final Year
  • Figure 17 Funding Source Share by Year
  • Figure 18 Oncology Growth
  • Figure 19 Neurology Growth
  • Figure 20 Cardiology Growth
  • Figure 21 Other Application Growth
  • Figure 22 Pharmaceutical Growth
  • Figure 23 Venture Growth
  • Figure 24 Clinical Growth
  • Figure 25 Other Funding Growth
  • Figure 26 2020 Clinical Laboratory Fee Schedule